Abstract Estimated worldwide incidence of tegumentary leishmaniasis (cutaneous leishmaniasis [CL] and mucocutaneous leishmaniasis [MCL]) is over 1.5 million cases per year in 82 countries, with 90 % of cases occurring in Afghanistan, Brazil, Iran, Peru, Saudi Arabia and Syria. Current treatments of CL are poorly justified and have suboptimal effectiveness. Treatment can be based on topical or systemic regimens. These different options must be based on Leishmania species, geographic regions, and clinical presentations. In certain cases of Old World CL (OWCL), lesions can spontaneously heal without any need for therapeutic intervention. Local therapies (thermotherapy, cryotherapy, paromomycin ointment, local infiltration with antimonials) are good options with less systemic toxicity, reserving systemic treatments (azole drugs, miltefosine, antimonials, amphotericin B formulations) mainly for complex cases. The majority of New World CL (NWCL) types require systemic treatment (mainly with pentavalent antimonials), either to speed the healing or to prevent dissemination to oral-nasal mucosa as MCL (NWMCL). These types of lesions are potentially serious and always require systemic-based regimens, mainly antimonials and pentamidine; however, the associated immunotherapy is promising. This paper is an exhaustive review of the published literature on the treatment of OWCL, NWCL and NWMCL, and provides treatment recommendations stratified according to their level of evidence regarding the species of Leishmania implicated and the geographical location of the infection.
intervention. L. major can heal spontaneously in 40-70 % of cases at 3 months and close to 100 % at 12 months. Spontaneous cure rates (CRs) for L. tropica are 1 % at 3 months, 68 % at 12 months and usually close to 100 % in 3 years [2] [3] [4] . No data are available for L. infantum. However, there are no definitive data about whether the residual scarring is smaller in treated patients than in those who are not treated. In certain cases, when there are few (fewer than four) lesions, the lesions are small (\4-5 cm), lesions are not localized on joints or esthetically compromised areas (eyelashes, lips), and there are no signs of lymphangitic dissemination or immunosuppression, local therapies (thermotherapy, cryotherapy, paromomycin ointment, local infiltration with antimonials) are good options that offer less systemic toxicity and the possibility for ambulatory treatment. Hence, systemic treatment (azole drugs, miltefosine, antimonials, amphotericin B formulations) for OWCL is thus reserved for complex cases.
Lesions of NWCL caused by L. mexicana may resolve spontaneously within 3-4 months; meanwhile, those caused by L. braziliensis, L. panamensis, L. guyanensis and L. peruviana may take more than 6 months [5, 6] . Moreover, NWCL lesions can secondarily disseminate to adjacent skin or mucosa, causing an MCL (NWMCL). Spread to the mucosa takes place in 2-30 % of untreated cutaneous cases (low risk with L. amazonensis and with L. guyanensis, 10 % with L. panamensis and up to 30 % with L. braziliensis). The development of mucosal affectation depends on various factors, such as the quantity (more than four lesions), the size ([4 cm) and the location (more on the upper part of the body) of lesions, as well as the duration of the lesions ([4 months), the nutritional and immune status of the patient, the virulence of the strain, and a suboptimal and insufficient treatment. The highest-risk geographical areas for NWMCL are the Andean and the Amazonian regions [7] . The common practice for NWCL is to treat the majority of CL types with systemic treatment, mainly pentavalent antimonials administered intravenously or intramuscularly. However, this measure may not guarantee total prevention of later MCL, which has been found in \5 % of cases [8] . Moreover, a high rate of adverse effects, the length of treatment and relapses in up to 25 % of cases highlight the limitations of such therapy. Evidence of other treatments varies among the different Leishmania species. Published data referring to L. braziliensis, L. mexicana or L. panamensis is quite profuse; meanwhile, for others such as L. amazonensis, L. lainsoni, L. naïffi, L. peruviana or L. venezuelensis, data are very scarce [8] . Treatment is always required for NWMCL as these types of lesions are potentially serious, and recurrence and relapse are frequent. The treatment is based upon antimonials and pentamidine; however, randomized clinical trials are scarce and the associated immunotherapy is promising [9] .
The objectives of this article are to exhaustively review the literature on OWCL, NWCL and NWMCL treatment; to analyse the methodology and results of the reviewed studies; to give treatment recommendations based on the leishmaniasis presentation form, country of origin and Leishmania species; and, finally, to stratify the strength of the recommendations based on the Infectious Diseases Society of America (IDSA) grade classification.
Methods
At the Tropical Medicine Unit of Ramón y Cajal Hospital in Madrid, Spain, the medical literature was searched, using databases such as MEDLINE, EMBASE, Web of Science and the Cochrane Library database. No limits were placed with respect to the date of publication. No language restrictions were imposed. The chosen search terms were 'old world cutaneous leishmaniasis' OR 'cutaneous leishmaniasis' OR 'leishmaniasis recidivans' OR 'diffuse cutaneous leishmaniasis' OR 'new world cutaneous leishmaniasis' OR 'mucocutaneous leishmaniasis' OR 'cutaneous leishmaniasis' OR 'new world diffuse cutaneous leishmaniasis' OR 'new world leishmaniasis' and 'treat- Bibliographical references from the included studies were also reviewed. The reference sections of primary studies, narrative reviews and systematic reviews were examined to search for additional primary studies that might have been missed during the electronic search.
Initially, only clinical trials were selected in order to obtain data with the highest-grade evidence. In the absence of good-quality evidence studies, a second review was conducted in order to obtain CR information. Later searches included original articles where data on results and treatment regimens were shown, such as large case series and multicentre studies, and also case reports when relevant results were reported.
Data collected and analysed for each of the selected articles were the methodology, treatment regimens (doses and duration), CRs (always using the last CR reported after the longest period of follow-up; when not specified, the intention-to-treat CR is given; when data of per-protocol CR is known, this is also reported), the country in which the study was performed and the Leishmania species isolated. These data were summarized in tables for each of the leishmaniasis forms of presentation studied.
Based on the methodology and the results of the studies, treatment recommendations were outlined for each leishmaniasis presentation form, country of origin and Leishmania species. The strength of such recommendations was stratified based on the IDSA grade classification (Table 1) [10, 11] . In this system, letters A-E signify the strength of the recommendation for or against a therapeutic measure and the roman numerals I-III indicate the quality of evidence supporting the recommendation [10, 11] . The strength of the recommendation was given based on several factors, such as the number of studies performed, the methodology of the studies, the number of patients included, if the specific Leishmania sp. was isolated or the time of follow-up.
3 Treatment for Cutaneous Leishmaniasis: Physical Therapies Table 2 .
Physical Therapies for Old World Cutaneous Leishmaniasis (OWCL)

Thermotherapy
The mechanism of action of thermotherapy is based on the ability to directly destroy the parasite through the application of heat. Several randomized clinical trials have compared thermotherapy with other therapeutic alternatives. One of them demonstrated that it achieved the same efficacy (CR 54.3 %) as intralesional antimonials (CR 59.8 %) in Afghanistan (L. tropica) [12] . Later, other studies undertaken in Iran proved the superiority of thermotherapy with radiofrequency (CR 80.7 %) compared with intralesional antimonials (CR 55.3 %) [13] . A third study comparing thermotherapy with intravenous antimonials in Iran and Kuwait (L. major) obtained similar CRs but with much fewer side effects than parenteral antimonials (CR thermotherapy 48 %; CR intravenous antimonials 54 %) [14] .
CO 2 Laser
The CO 2 laser is capable of thermolysis on damaged tissues, and causes hardly any damage to the surrounding healthy tissue [15] . Recently, a randomized clinical trial was conducted in Iran in which thermotherapy using a CO 2 laser was compared with combined therapy with cryotherapy plus intralesional antimonials. The results of the trial demonstrated that one single session of thermotherapy with a CO 2 laser was more effective (CR 93.7 %) than the combined therapy (CR 78 %) [16] .
Photodynamic Therapy
Light-mediated cytolysis of Leishmania parasites is a new technique in the treatment of CL. A randomized controlled trial performed in Iran showed evidence that photodynamic therapy can be used safely as a rapid and highly effective alternative treatment choice for OWCL (CR 93.5 %) [17] .
Cryotherapy
Cryosurgery is not a new mode of treatment. Using a CO 2 cryomachine, a CR of 100 % in 30 patients in Saudi Arabia with L. major CL was obtained [18] . Later, liquid nitrogen was demonstrated to have the same qualities, reaching an efficiency rate of over 95 % in Jordan, Israel and Greece [19] [20] [21] [22] and of 78 % in Turkey [23] . Several clinical trials have highlighted the superiority of the combination of cryotherapy and intralesional pentavalent antimonials with CRs from 89.5 to 100 %, compared with using any of the two therapies on their own for L. major and L. tropica CL in the United Arab Emirates and in Iran [24] [25] [26] [27] . However, the combination of nitric oxide (NO) in the form of an ointment at 3 % with cryotherapy did not prove more effective than cryotherapy on its own in a randomized trial in Iran with CRs of 83.3 and 74.1 %, respectively [28] .
A clinical trial performed in Iran in a pediatric population demonstrated that cryotherapy (CR 52.5 %) was more 
Thermotherapy
The direct application of heat can accelerate the cure of the lesions [31] . The first data about its efficacy were obtained in Guatemala with L. mexicana and L. braziliensis, reaching a response rate similar to those of antimonials of higher than 70 % [32] . However, in two studies undertaken in Colombia, the response rate only reached about 40-60 % [33, 34] , but without the adverse reactions or the cost of antimonials, which positions thermotherapy as a first-line treatment in this country.
Topical Nitric Oxide
The first studies were performed with an ointment of Snitroso-N-acetyl penicillamine (SNAP), a compound that generates NO. The results were promising when it was applied for 10 days in Ecuador on infections by L. braziliensis [35] . [37] . Administered as an ointment (15 % paromomycin sulphate ointment in 12 % methylbenzethonium chloride) in Iran for L. major twice a day for 20 days, it achieved an efficacy of up to 77 % compared with 27 % for placebo [38] .
Later, the randomized clinical trials for L. major infection that were developed in Iran with topical paromomycin (15 % paromomycin sulphate ointment in 10 % urea) administered for 14 days demonstrated a significant improvement on finalizing the treatment when compared with a placebo group. But after 105 days of follow-up, the CR was the same as that of the placebo group (CR 68 %) [2] . In another randomized clinical trial in Tunisia for L. major infection, patients were treated with topical paromomycin (15 % paromomycin sulphate ointment in 10 % urea) for 14 days. This treatment was of no greater efficacy after 105 days of follow-up (CR 66.7 vs 92.3 %) than placebo [4] .
These results encouraged questions over whether the difference between the response rates was related to the duration of the treatment. For this reason, a trial was developed in Iran for L. major and L. tropica infections in which 4 weeks of therapy was compared with 2 weeks of therapy. The initial CRs were significantly higher in the 4-week group. After 105 days of follow-up, the results were still better for the prolonged therapy, albeit differences were no longer as significant (CR 57 vs. 43 %) [39] . This suggests that the differences found in the CR were probably not due to the duration of the treatment and, in fact, in a recent Iranian clinical trial with topical paromomycin applied for 30 days, the CRs were no higher than those for placebo after 60 days' follow-up (CR 67 and 69 %, respectively) [40] . These differences are likely to be due to the components of the ointment; for the treatment of OWCL by L. major, the combination of 15 % paromomycin sulphate plus 12 % methylbenzethonium chloride ointment was more effective than 15 % paromomycin sulphate ointment plus 10 % urea.
Different studies have aimed to investigate whether or not topical paromomycin is superior to other local therapies. In Iran, two different studies compared intralesional administration of antimonials and topical administration of paromomycin (15 % paromomycin sulphate ointment in 10 % urea) for infections by L. major and L. tropica. In the first study, both treatments achieved low response rates, even though intralesional antimonials were higher (16.6 vs. 41.7 %) [41] . In the second study, the response rate was higher in both cases and without any significant differences between the two local therapies (67 % intralesional antimonials vs. 69 % paromomycin) [42] .
More recently, in a study in Tunisia, the efficacy of a new combination of ointment (WR279,396) composed of paromomycin at 15 % plus gentamycin at 0.5 % applied twice daily for 20 days for L. major infections when compared with placebo obtained response rates of 94 and 71 %, respectively [43] . [50] .
A randomized clinical trial in Iran, probably for infections by L. major and L. tropica, compared the efficacy of weekly intralesional antimonials up to a maximum of 12 injections versus topical paromomycin administered as an ointment twice daily until the resolution of the lesions, taking on average 45 days. Despite the response rate not being very high, the antimonials proved to be more effective (CR 41.7 %) than paromomycin (CR 16.6 %) [41] .
In Saudi Arabia, a randomized clinical trial compared parenteral therapy with antimonials (15 mg Sb v? /kg/day, up to a maximum 850 mg Sb v? /kg, daily on 6 days a week until 12 injections) with intralesional therapy with antimonials (0.2-0.8 ml/lesion/day on alternate days over a 30-day period). The response rates were found to be similar for systemic therapy (CR 84 %) and local therapy (CR 88 %) [44] .
Another non-randomized clinical trial was performed in Saudi Arabia that compared different administration doses for intralesional antimonials. Hence, intralesional antimonials until complete blanching were compared at three different doses: daily, on alternate days and weekly. The administration on alternate days (CR 97 %) or in weekly doses (CR 91 %) proved to be more effective than daily administration (CR 67 %) [45] .
A randomized double-blind clinical trial carried out in Sri Lanka (L. donovani) reached a CR of 100 % when injecting intralesional antimonials after an average of one to six sessions. These results were compared with those of administration of intralesional 7 % hypertonic sodium chloride, without finding any statistically relevant differences between CRs. However, lesions that received antimonials healed faster [51] .
In India, a prospective comparative study was done (L. tropica) in which the administration of two different doses of five to seven injections of intralesional antimonials given according to the size of the lesion (total amount 0.5-5 ml per lesion per injection) were compared. In one group, the injections were administered weekly for 5-7 weeks, and in the other group, the patients received two weekly injections for 3-4 weeks. The CRs of both, long (CR 92 %) and short (CR 96 %), did not show any significant differences, even though the CR was faster for the short-term treatment [52] .
On the other hand, there are various studies about the benefits of the combination of intralesional antimonials with other therapeutic options. A study undertaken in Iran (probably L. major or L. tropica) showed that the efficacy of the combination of intralesional antimonials with cryotherapy was higher than its administration as monotherapy (CR 92.3 vs. 50 %) [25] . In Pakistan (L. tropica) the combination of intralesional and parenteral pentavalent antimonials proved to be more effective than the intralesional antimonials on their own (CR 75 vs. 55 %) [53] . Similarly, in the Yemen (probably L. major or L. tropica) a randomized trial found that the CRs achieved with combined therapies based on the combination of intralesional pentavalent antimonials either with intramuscular antimonials (CR 93.3 %) or with oral ketoconazole (CR 92.3 %) were higher than intralesional antimonials on their own (CR 58.3 %) [54] . However, in an uncontrolled prospective comparative study in military troops in Afghanistan (L. major), the combination of intralesional pentavalent antimonials and cryotherapy was not superior to monotherapy with intralesional antimonials [55] .
In terms of side effects, local itching, erythema, pain during administration (which occasionally requires local anaesthesia), as well as hyperpigmentation of the lesion, which tends to resolve spontaneously after a couple of months, stand out [44, 56] . In other cases, the intralesional injections can cause complications when a bacterial overinfection occurs, especially when the lesions are located on the face or on extremities [57] .
Topical Imidazole Drugs
Formulated as an ointment, topical applications of 1 month of clotrimazole and miconazole have been used in Saudi Arabia. With clotrimazole, a CR of 16 % was reached, while none of the cases treated with miconazole were definitely cured [58] .
The only double-blind randomized clinical trial was carried out in Saudi Arabia (L. major), where the efficacy of 1 % clotrimazole ointment was compared with that of 2 % miconazole ointment, both applied for 30 days: 67 % were cured completely or healed predominantly in the clotrimazole group, but only 35 % of the patients in the miconazole group responded clinically [59] .
Topical ketoconazole was also tested in Afghanistan, but it did not significantly change the course of the lesions [60] . [61, 62] . Another study also developed in Ecuador showed no significant differences between the efficacy of the topical paromomycin (CR 79.3 %) treatment and the parenteral pentavalent antimonials (CR 91.7 %), even though the time until cure was longer with paromomycin [63] . However, it turned out to be ineffective in the treatment of NWCL by L. mexicana and L. chagasi in Honduras (CR 5.5 %) [64] . On several occasions, the possibility of combining topical paromomycin with a short-course treatment of pentavalent antimonials has been considered, in order to increase its efficacy and decrease secondary effects. The results obtained are disparate. In a randomized trial performed in Colombia with L. panamensis and L. braziliensis infections, topical paromomycin-methylbenzethonium chloride and injectable meglumine antimoniate in a shortcourse treatment regimen of 3-7 days did not exceed the 58 % CR and was less effective than antimonials on their own in a conventional treatment of 20 days [65] . However, in another study, also undertaken in Colombia but with a higher proportion of L. panamensis infections, the combination of topical paromomycin-methylbenzethonium chloride and injectable meglumine antimoniate in a shortcourse treatment of 7 days reached a CR of 90 % [66] . This leads us to consider that short-course combined therapy could be less effective for L. braziliensis infections. 
Recommendations
Intralesional
Pentavalent Antimonials The experience with intralesional pentavalent antimonials is virtually nil. In a Brazilian study developed in 74 patients with NWCL by L. braziliensis, meglumine an-timoniate was injected intralesionally in the four cardinal points of the lesion, until achieving complete blanching, every 3-7 days and for a total of one to five sessions with a CR of 80 % after 10 years of follow-up [67] Grade: BIII. Recently, a randomized clinical trial was performed for NWCL caused by L. braziliensis in Bolivia; three doses of meglumine antimoniate were injected intralesionally with 70 % CR at 6 months follow-up [68] Grade: CI.
Oral Drug Therapy
In the case of fluconazole, its efficacy (CR 79 %) and tolerance compared with placebo was demonstrated in a clinical trial in which a dose of 200 mg/day was administered for 6 weeks in Saudi Arabia (L. major) [69] . A recent clinical trial conducted in Iran (L. major) obtained a higher response rate when the dose of fluconazole was increased from 200 to 400 mg per day for 6 weeks (CR 81 %) [70] .
Ketoconazole at a dose of 600 mg/day for adults and 10 mg/kg/day for children for 30 days obtained significantly higher CRs (89 %) than intralesional antimonials in a randomized trial in Iran (L. major and L. tropica) [71] . However, the dose of 400 mg/day for 30 days proved ineffective in Turkey (CR 0, and 21.9 % had incomplete healing) [72] . These poor results were possibly due to the high proportion of infection by L. tropica. Another trial developed in Kuwait with the aim of determining the most effective doses of ketoconazole compared doses of 600 mg/day (CR 80 %) and 800 mg/day (CR 81.8 %) for 6 weeks without any evidence of a difference between regimens [73] .
Several randomized clinical trials have compared itraconazole with placebo. Mild results were obtained in India (L. tropica), where a dose of 4 mg/kg/day for 6 weeks elicited CRs of 66.7 % [74] , and good results were obtained in Iran (L. major), where a dose of 7 mg/ kg/day for 3 weeks elicited CRs of 95 % [75] . Nonetheless, itraconazole at a dose of 200 mg/day for 8 weeks in Iran (L. major) presented lower CRs of 59 % [76] .
One case described a cure of OWCL by L. infantum treated with oral posaconazole [77] .
Miltefosine
There is scarce experience in the use of miltefosine for treating OWCL. It has been mainly used against L. major infections, for which response rates vary between 87 and 100 % [78, 79] . The only clinical trial performed for OWCL studied L. major infections in Iran and concluded that oral miltefosine (CR 81.3 %) is as effective as the intralesional antimonials (CR 80.6 %) [80] . The applicability of miltefosine for OWLC due to L. tropica or L. infantum infections is only based on a few case reports [81, 82] . 
Recommendations
Azole Drugs
There is evidence that ketoconazole at a dose of 600 mg daily taken orally over 28 days obtained a response rate of between 76 and 90 % in NWCL in Guatemala and Panama for infections by L. mexicana, L. panamensis, but not by L. braziliensis [83, 84] . Itraconazole at doses of 400 mg daily over 28 days did not show any benefits in a randomized trial for the treatment of undifferentiated NWCL in Colombia (CR 25 %) [85] .
Miltefosine
Miltefosine has been used in the treatment of several NWCL species with variable effi-cacy. First results were obtained in Colombia, where the most frequent species is L. panamensis and where CRs with miltefosine were [80 % [86, 87] . However, a later clinical trial also performed in Colombia found a CR lower than 70 %, probably due to the high proportion of L. braziliensis cases [88] . Moreover, in NWCL in Guatemala for infections by L. braziliensis and L. mexicana, the CR with miltefosine at 6-month follow-up was \50 % [86] . Another study, performed in Bolivia in an area with a predominance of L. braziliensis, compared oral miltefosine with parenteral pentavalent antimonials, did not find differences between them, and reported a CR [80 % among those treated with miltefosine [89] . In Brazil, the response rate for L. braziliensis was 75 % [90] , and slightly lower (CR 71.4 %) for L. guyanensis [91] . A recent study performed in Germany with imported leishmaniasis found in travelers, collected data from eight patients with cutaneous lesions caused by L. braziliensis after travelling to Bolivia, Costa Rica, Peru, Ecuador or Brazil and reported a 63 % overall CR [92] . The varying and lower rate of efficacy observed in the clinical trials probably reflects the lower intrinsic sensitivity of L. braziliensis strains to miltefosine. It has been postulated that this is due to a reduced capacity of L. braziliensis to internalize miltefosine from the extracellular medium [93] . Recently, the first clinical trial evaluating the effect of oral miltefosine for children aged 2-12 years with NWCL, in an area in Colombia where L. panamensis and L. guyanensis infections predominate, was performed. It showed that miltefosine 1.8-2.5 mg/kg/day for 28 days, with a CR of 82.7 %, was not inferior to parenteral meglumine antimoniate 20 mg Sb v? /kg/day intramuscularly for 20 days, with a CR of 69 %, and had lower toxicity [94] .
Other Oral Treatments
Azithromycin initially demonstrated, in vitro and in animal models, its capacity against L. major [95] . Later, several non-randomized trials obtained good results in patients with cutaneous and mucocutaneous lesions [95] [96] [97] . However, the only randomized clinical trial showed that a dose of 500 mg per day for 28 days had very little efficacy (CR 45.5 %) in the treatment of NWCL by L. braziliensis in Argentina [98] .
Several studies have evaluated the efficacy of allopurinol for the treatment of NWCL. Despite some hopeful results [99] , the clinical trials showed no efficacy as monotherapy in Colombia in infections by L. panamensis or L. braziliensis (CR 29.1 %) [98] , or when combined with probenecid in Ecuador (CR 42.8 %) [100] . [101] have proven effective in Eastern Africa, the Middle East and the Mediterranean countries [102, 103] , but with different response rates between species, with CRs of 75-98 % for L. major and 41-53 % for L. tropica [12, [103] [104] [105] [106] .
Recommendations
There are few studies in children. One was conducted in Algeria and demonstrated superiority over placebo when administrated for 15 days (55 vs. 48 %) [107] . Another study conducted in Iran showed a lower efficacy (74.2 vs. 80.6 %) in treating acute (\3 months) lesions in children (B15 years old) versus adults [108] .
Several studies have been conducted in Iran examining the combination of drugs at the habitual doses of parenteral antimonials, with the intention of increasing their efficacy, and have obtained disparate results. The combination of oral allopurinol at doses of 15-20 mg/kg/ day for 20 days (L. tropica) proved to be more effective than monotherapy but only achieved a CR of 46 % [109] . However, in another study, the combined therapy of parenteral antimonials (30 mg Sb v? /kg/day) and oral allopurinol (20 mg/kg/day) for 20 days reached higher CRs (80.6 %) [110] . A clinical trial (L. major) found a CR of 81.3 % when using the combination of parenteral antimonials (20 mg Sb v? /kg/day) and oral pentoxifylline (400 mg three times daily) for 20 days, superior to the 51.6 % CR obtained by antimonials as monotherapy [111] . The combination of topical 5 % imiquimod cream three times per week with parenteral pentavalent antimonials for 14 days does not seem to result in additional benefits (CR 50.8 %) [105] . 
Liposomal Amphotericin B (LAB)
Experience with using liposomal amphotericin B (LAB) for the treatment of OWCL is very scarce. The majority of cases that required systemic parenteral treatment received pentavalent antimonials. However, their toxicity encourages the increasing choice of LAB by more and more professionals, especially in those situations where pentavalent antimonials have failed [112] [113] [114] [115] [116] [117] .
A study conducted in the USA collected therapeutic response of LAB treatment for OWCL at doses of 3 mg/kg/day up to ten doses, given within a 21-day period, in ten travelers (five from Iraq and five from Afghanistan) with isolated species of L. major (three cases) and L. tropica (two cases). The general response rate when finishing the treatment was 84 %. However, all the failed attempts responded in a second cycle [118] . [100, [119] [120] [121] , with the exception of L. guyanensis infection in French Guinea where pentamidine is the first-choice treatment [122] . Despite this, other cases of NWCL by L. guyanensis in Peru had a response rate to pentavalent antimonials of [90 % [123, 124] or of 73.3 % [125] . Similarly, L. mexicana responds poorly in Guatemala (CR 57 %) [32] , but very well in Mexico (CR 100 %) [124] .
Due to the potential toxicity of the systemic antimonials, several trials were designed to find the lowest effective doses. Intravenous sodium stibogluconate 20 mg/kg/day was compared with intravenous doses of 10 mg/kg/day to treat cases of NWCL caused by L. braziliensis or L. panamensis in Panama, and showed that CRs were significantly lower with the lower doses (CR 76.2 vs. 100 %) [126] . Later, in another study also conducted in Panama with infections by L. panamensis and to a lesser extent by L. mexicana, it was found that, with doses of antimonials less than 13 mg/kg/day for 20 days, the CR was only 68 % [82] . Along the same lines, a randomized clinical trial was performed in Guatemala with L. braziliensis and L. mexicana infections; meglumine antimoniate was used at doses of 15 mg/kg/day for 15 days, and the CR reached 64 % [62] . However, in later studies conducted in Guatemala and Panama, where the duration of treatment was cut to fewer days, it was proven that favorable results could also be obtained by administering 20 mg/kg/day for fewer than 20 days, (CR 90 % and 95 %, respectively) [127, 128] .
The Pan-American Health Organization (PAHO) guide for the treatment of infectious diseases recommends sodium stibogluconate 20 mg Sb v? /kg/day intramuscularly or intravenously for 20 days as first-line treatment for all Leishmania spp. [129] .
Combination therapy has been used in some studies. Topical administration of the immunomodulator imiquimod every other day for 20 days as adjunct therapy to pentavalent antimonials has been tested in Peru (CR 72 %). Although no significant difference among CRs was observed, imiquimod accelerated cure in comparison with antimonials alone in patients with relapsing lesions [130] .
The use of immunotherapy based on the administration of a vaccine containing dead promastigotes of L. amazonensis associated with low doses of pentavalent antimonials was tested in Brazil in a randomized double-blind study.
Not only did it prove to be highly effective (CR 100 %), but the lesions were also cured faster than with the conventional doses of antimonials [131] . Injected autoclaved L. mexicana and L. amazonensis promastigotes together with Bacillus Calmette Guerin tuberculosis vaccine (BCG) have been tested in combination with systemic antimonials in Venezuela, with high success (CR 95.7 %) [132] . [118, [133] [134] [135] . Not many controlled clinical trials are able to give a clear response for LAB in NWCL. In one, undertaken in Bolivia for L. braziliensis infection, LAB proved to be more effective (CR 85 %), better tolerated and more cost effective than antimonials [136] . Another clinical trial in Brazil, mainly for infections by L. braziliensis, found that low doses of LAB achieved a high CR (81 %), although lower than that obtained by pentavalent antimonials (CR 100 %) but with fewer side effects [137] .
Pentamidine Isethionate
Several studies have compared the efficacy of pentamidine isethionate with pentavalent antimonials when treating NWCL. The results have been disparate according to different geographical locations and species involved. Administered at intravenous or intramuscular doses of 3-4 mg/kg/day every other day for 4-10 injections, it is the drug of choice in French Guyana, where over 90 % of infections are due to L. guyanensis [138, 139] . Similarly, in Brazil with primarily L. braziliensis, and in Surinam with L. guyanensis, CRs of 73-100 % have been obtained [140, 141] . Nonetheless, recent clinical trials have demonstrated a low response in those cases acquired in Brazil and caused by L. guyanensis (CR 58.1 %), but with no significant differences in the CR in response to antimonials [142] . In Colombia, where the majority of infections are caused by L. panamensis, CRs of up to 95 % have been reached in patients treated with four injections of 3 mg/kg/day every other day and with a toxicity comparable to that of antimonials [85, 143] . The results obtained in Peru with L. braziliensis were less favorable; the efficacy of pentamidine was 35 % compared with 78 % with antimonials [121] .
Paromomycin
Data regarding the response to paromomycin are fundamentally limited to topical treatment, due to the lack of knowledge about their efficacy when administered parentally. Once again, the results of the different studies are disparate and the size of the groups under study rather small. Intramuscular paromomycin administered at a dose of 12-18 mg/kg/day for 14 days obtained CRs as low as 50-60 % in Colombia and in Belize [144, 145] ; however, CRs in Brazil reached over 90 % [146] . It is likely that these differences are due to a heterogeneous response in different species. In any case, it is necessary to conduct more studies to be able to determine with any precision the efficacy of paromomycin and to evaluate it for use as an alternative treatment to pentavalent antimonials. . In a randomized clinical trial conducted in Bolivia and Peru, the combination of itraconazole with amphotericin B did not result in any additional benefit (CR 80 %) [149] . Grade: CIII.
Recommendations
Miltefosine
The results of several studies carried out using miltefosine in Colombia and Guatemala demonstrated an important variability in the CR depending on the geographical area and the Leishmania species isolated [86] . Good results observed in Colombia suggest that miltefosine may also be a good option for NWMCL. Similarly, a non-randomized clinical trial carried out in Bolivia, using miltefosine at doses of 2.5-3.3 mg/kg/day for 28 days, reached a CR of 83 % for moderate NWMCL and 58 % for severe cases, versus 50 % among those treated with AB [150] . Subsequently, the same patients were re-evaluated 24 months after the beginning of the trial. It was observed that only 2 of 41 patients relapsed. Prolonging treatment from 4 to 6 weeks was also evaluated and was seen to increase the CR to 75 % [151].
Parenteral Treatment
Pentamidine
Two studies published by the same research group from Brazil, in patients with moderate-to-severe NWMCL in whom pentamidine was used as first-line treatment, obtained good CRs (90 and 94 %, respectively) [152, 153] . In a more recent study, again from Brazil, in which 140 mainly slight NWMCL cases were analyzed, pentamidine obtained the same CR as antimonials [154] . The PAHO guide for the treatment of infectious recommends pentamidine as a second-line therapeutic option. Grade: BII [129] .
Paromomycin
There are two published case series from Brazil in which patients with NWMCL were treated with paromomycin sulfate at doses of 16 mg/kg/day for 20 days and obtained a CR of between 48 and 67 % [155, 156] . A randomized clinical trial performed in Peru found that paromomycin at doses of 14 mg/kg/day over 21 days was ineffective for the treatment of NWMCL (CR 0 %) [157] .
Pentavalent Antimonials
Studies evaluating the efficacy of pentavalent antimonials in NWMCL are scarce, and the majority is based on a small sample group. CRs vary from 30 to 90 % [158] [159] [160] [161] . A meta-analysis that includes the different studies published regarding the use of pentavalent antimonials in NWMCL until 2007 determined a global CR of around 67 %, which appears to be conditional on the species implicated, the geographical location and the severity of the lesions [162] [163] [164] . The standard doses are 20 mg Sb v? /kg/day for 28-30 days.
Because of the therapeutic failure rate of antimonials (up to 42 %) [158] and the frequent relapses (up to 20 %) [161] , in many cases it is necessary to repeat the cycles of antimonials, despite their potential toxicity. Therefore, attempts have been made to find other drugs that, when combined with antimonials, improve the response rate. Tumor necrosis factor (TNF)-a appears to play an important role in the inflammatory response of the host and therefore in their healing [165, 166] . Pentoxifylline has demonstrated the ability to inhibit gene transcription of TNF-a, thus decreasing leukocyte adhesion and migration [167] . In a preliminary study, pentoxifylline was combined with antimonials in patients for whom antimonials had previously failed, obtaining a response in nine of the ten patients treated within 1 year [168] . These results gave rise to the development of a randomized clinical trial that compared combination therapy of pentoxifylline and antimonials versus antimonials alone. Both groups had the same CR (100 %); however, cure was accelerated, and the relapse rate reduced, in patients receiving pentavalent antimonials combined with pentoxifylline when compared with patients receiving antimonials alone [169] . In fact, the PAHO guide for the treatment of infectious diseases recommend antimonials plus pentoxifylline for 30 days as the first-line therapeutic option for NWML [129] . /kg/day (without upper limit of 850 mg/day) for 30 days ? pentoxifylline (oral) 400 mg 3 times a day for 30 days
Recommendations
Amphotericin B and LAB
Amphotericin B at a total dose of 2.25 g proved effective (CR 88 %) in Bolivia in 211 patients with NWMCL by L. braziliensis [149] . In a small randomized study conducted in Bolivia and Peru, doses of 50 mg every 2 days until lesions healed was very effective (CR 90 %), and the addition of oral itraconazole for 41 days did not improve the CR (80 %) [149] . Grade: BII.
Results with LAB were better than with AB, even in those cases in which therapy with antimonials had previously failed. Three published case series conducted in Brazil included a total of 15 patients with NWMCL caused by L. braziliensis who received LAB 2-3 mg/kg/ day until a total dose of 40-50 mg/kg and achieved response rates of between 83.3 and 100 % [154, 170, 171] . Recently, a short series of cases from Brazil was published where patients received an average total dose of 35 mg/kg of LAB, yielding a CR of 100 % and no recurrence at 25 months of median follow-up. Given the results, the authors raised the possibility that lower doses of LAB than those routinely recommended could be sufficient, thus reducing the toxicity and cost of treatment [172] . Grade BIII. [173] and L. panamensis [174] have been described. The therapeutic response to NW diffuse CL (NWDCL) is usually very poor. Pentavalent antimonials are the firstline drugs and are usually effective in the initial stages; however, in more advanced stages, recurrence is the usual outcome [175, 176] . Other drugs such as miltefosine have been tested with disparate results and in discouraging terms [177] [178] [179] . AB was tested with favorable results but lesions recurred a few months later [175] . There are no data regarding lipid formulations of AB.
Conclusions
Despite the lack of evidence, until the 1990s, parenteral pentavalent antimonials were the chosen drugs for the treatment of OWCL. However, things have changed recently. The fact that a high percentage of OWCL cases cure spontaneously, together with the good results obtained from different studies published about local therapies (thermotherapy, paromomycin ointment, intralesional antimonials), mean the latter are currently considered firstline treatments in most cases. Moreover, the combinations of local therapies and parenteral pentavalent antimonials have an additional therapeutic effect. The different oral therapies (azole drugs, miltefosine) decrease the costs derived from hospitalization. Little is known about the efficacy of LAB, as the current knowledge is limited to case series fundamentally based on patients in whom other treatments had previously failed.
For NWCL, local treatment can be considered in specific situations. However, the established treatment is the systemic one, although its efficacy depends on the species of Leishmania involved and the geographical area. Pentavalent antimonials are the most used but cause side effects, and a prolonged duration of the treatment is needed. For L. amazonensis and L. peruviana, pentavalent antimonials seem to be the best treatment option. In the case of L. mexicana, oral treatment with ketoconazole or miltefosine is recommended. In the case of L. guyanensis and L. panamensis, pentamidine and miltefosine have been proposed as alternative treatments. In the case of L. braziliensis, AB and LAB are good alternatives. Recurrence in any case seems to respond best to LAB.
For NWMCL, it seems that systemic treatment is always the best option. The recommended drugs are pentavalent antimonials (for 30 days and best associated with pentoxifylline), AB or LAB. Many more randomized clinical trials identifying the species of Leishmania involved, and conducted in different geographical areas, are required in order to establish the first-line drugs and treatment of recurrences.
